Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma

Ou,Yingfu; Xia,Rongjun; Kong,Fanyong; Zhang,Xiaokang; Yu,Shengjin; Jiang,Lili; Zheng,Linlin

doi:10.3892/ol.2016.4147

Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma

Authors:
- Yingfu Ou
- Rongjun Xia
- Fanyong Kong
- Xiaokang Zhang
- Shengjin Yu
- Lili Jiang
- Linlin Zheng
View Affiliations

Affiliations: Institute of Molecular Medicine, Medical College, Eastern Liaoning University, Dandong, Liaoning 118000, P.R. China
Published online on: January 26, 2016 https://doi.org/10.3892/ol.2016.4147
Pages: 1823-1828

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increased expression of the human DEK proto-oncogene (DEK) gene has been associated with numerous human malignancies. The DEK protein is associated with chromatin reconstruction and gene transcription, and is important in cell apoptosis. The present study aimed to elucidate the role of DEK with regard to gastric adenocarcinoma tumor progression and patient prognosis. DEK protein expression was analyzed using immunohistochemistry in 192 tumors paired with adjacent non‑cancerous gastric mucosa that had been surgically resected from patients with primary gastric adenocarcinoma. The association between DEK expression and the clinicopathological characteristics of the patients was evaluated using the χ2 test and Fisher's exact test. The survival rates of the patients were calculated using the Kaplan‑Meier method. Cox analysis evaluated the association between the expression of DEK and the survival rate of the patients. The DEK protein was expressed in 84 patients with gastric adenocarcinoma (43.8%) and in 20 of the paired normal gastric mucosa tissues (11.5%). The DEK expression rate was found to be associated with tumor size (P=0.006), tumor grade (P=0.023), lymph node metastasis (P=0.018), serous invasion (P=0.026), tumor stage (P=0.001) and Ki‑67 expression (P=0.003). Furthermore, patients with gastric adenocarcinoma that expressed DEK had decreased disease‑free (log‑rank, 16.785; P<0.0001) and overall (log‑rank, 15.759; P<0.0001) survival rates compared with patients without DEK expression. Patients with late‑stage gastric adenocarcinoma that expressed DEK exhibited a lower overall survival rate compared with patients without DEK expression (P=0.002). Additional analysis revealed that DEK expression was an independent prognostic factor for the prognosis of gastric adenocarcinoma (hazard ratio, 0.556; 95% confidence interval, 0.337‑0.918; P=0.022). From the results of the present study, it can be concluded that the detection of DEK protein expression in gastric adenocarcinoma tissues may be important for the diagnosis and prognosis of patients, and may be a targeted therapy for the treatment of gastric adenocarcinoma.

View Figures

View References

1	Wang D, Wang L, Zhou J, Pan J, Qian W, Fu J, Zhang G, Zhu Y, Liu C, Wang C, Jin Z, He Z, Wu J and Shi B: Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma. PLoS One. 11:e1137542014. View Article : Google Scholar
2	Yang X, Takano Y and Zheng HC: The pathobiological features of gastrointestinal cancers (Review). Oncol Lett. 3:961–969. 2012.PubMed/NCBI
3	von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A and Grosveld G: The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol. 12:1687–1697. 1992. View Article : Google Scholar : PubMed/NCBI
4	Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H and Wells SI: Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol. 26:7506–7519. 2006. View Article : Google Scholar : PubMed/NCBI
5	Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC and Wells SI: Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res. 69:1792–1799. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wu Q, Li Z, Lin H, Han L, Liu S and Lin Z: DEK overexpression in uterine cervical cancers. Pathol Int. 58:378–382. 2008. View Article : Google Scholar : PubMed/NCBI
7	Orlic M, Spencer CE, Wang L and Gallie BL: Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer. 45:72–82. 2006. View Article : Google Scholar : PubMed/NCBI
8	Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M and Müller H: DEK expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI
9	Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA and Trama JP: Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer. 11:2342011. View Article : Google Scholar : PubMed/NCBI
10	Mohan S, Abdelwahab SI, Kamalidehghan B, Syam S, May KS, Harmal NS, Shafifiyaz N, Hadi AH, Hashim NM, Rahmani M, et al: Involvement of NF-κB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound pyranocycloartobiloxanthone A. Phytomedicine. 19:1007–1015. 2012. View Article : Google Scholar : PubMed/NCBI
11	Khaw AK, Yong JW, Kalthur G and Hande MP: Genistein induces growth arrest and suppresses telomerase activity in brain tumor cells. Genes Chromosomes Cancer. 51:961–974. 2012. View Article : Google Scholar : PubMed/NCBI
12	Lupescu A, Jilani K, Zbidah M and Lang F: Induction of apoptotic erythrocyte death by rotenone. Toxicology. 300:132–137. 2012. View Article : Google Scholar : PubMed/NCBI
13	Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R and Lin Z: Clinicopathological significance of DEK overexpression in serous ovarian tumors. Pathol Int. 59:443–447. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J and Lin Z: DEK overexpression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 13:366–345. 2013. View Article : Google Scholar : PubMed/NCBI
15	Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). New York, NY: Springer-Verlag New York. 2010.
16	Marchet A, Mocellin S, Ambrosi A, Morgagni P, Vittimberga G, Roviello F, Marrelli D, de Manzoni G, Minicozzi A, Coniglio A, et al: Validation of the new AJCC TNM staging system for gastric cancer in a large cohort of patients (n=2,155): Focus on the T category. Eur J Surg Oncol. 37:779–785. 2011. View Article : Google Scholar : PubMed/NCBI
17	Köbel M, Weichert W, Crüwell K, Schmitt WD, Lautenschläger C and Hauptmann S: Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. Virchows Arch. 445:456–464. 2004. View Article : Google Scholar : PubMed/NCBI
18	Lazăr D, Tăban S, Raica M, Sporea I, Cornianu M, Goldiş A and Vernic C: Immunohistochemical evaluation of the tumor neoangiogenesis as a prognostic factor for gastric cancers. Rom J Morphol Embryol. 49:137–148. 2008.PubMed/NCBI
19	Kappes F, Burger K, Baack M, Fackelmayer FO and Gruss C: Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem. 276:26317–26323. 2001. View Article : Google Scholar : PubMed/NCBI
20	Killeen MR: Integrating a neurobiological systems approach into child neglect and abuse theory and practice. J Child Fam Nurs. 2:406–407. 1999.PubMed/NCBI
21	Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, et al: The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 39:7465–7476. 2011. View Article : Google Scholar : PubMed/NCBI
22	Vinnedge Privette LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE and Wells SI: The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 30:2741–2752. 2011. View Article : Google Scholar : PubMed/NCBI
23	Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A and Aldaz CM: Breast cancer molecular signatures as determined by SAGE: Correlation with lymph node status. Mol Cancer Res. 5:881–890. 2007. View Article : Google Scholar : PubMed/NCBI
24	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
25	Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, et al: DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene. 29:4671–4681. 2010. View Article : Google Scholar : PubMed/NCBI
26	Lin L, Piao J, Ma Y, Jin T, Quan C, Kong J, Li Y and Lin Z: Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer. PLoS One. 9:e1112602014. View Article : Google Scholar : PubMed/NCBI
27	Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Bürkle A, Markovitz DM and Ferrando-May E: DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Mol Cell Biol. 28:3245–3257. 2008. View Article : Google Scholar : PubMed/NCBI
28	Khodadoust MS, Verhaegen M, Kappes F, et al: Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009. View Article : Google Scholar : PubMed/NCBI